Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.

Contributed by: Business Wire

Logo

Tags

Biotechnology

Health

Pharmaceutical

Clinical Trials

Oncology

Brenus Pharma

More Like This

Brenus Pharma Announces First Patients Dosed in its First-in-Human Trial Evaluating STC-1010, a Next-Generation Immunotherapy

Brenus Pharma Reports Favorable Tolerability and Clinical Signals in Early Preliminary Results of First-In-Human Study for STC-1010 in Unresectable Metastatic Stage Colorectal Cancer (MSS CRC) Patients

AACR 2026: First‑in‑Human STC‑1010 Data Show Favorable Safety and Early Immune Engagement in Metastatic MSS Colorectal Cancer

Brenus Pharma Announces FDA Acceptance of IND Application for STC-1010 (BreAK-CRC001) in MSS Metastatic Colorectal Cancer (mCRC)

Brenus Pharma Presented New Preclinical and Early Clinical Data in Colorectal Cancer During AACR Immuno-Oncology Conference 2026

George Alzeeb, PhD, Innovation Manager at Brenus Pharma, presenting the company’s latest preclinical data on STC-1010 — an off-the-shelf vaccine-based immunotherapy — during the Late-Breaking session at the American Association for Cancer Research (AACR) Annual Meeting 2025. This poster highlights the potential of STC-1010 to induce a robust anti-tumor response, supporting Brenus Pharma’s novel approach in immuno-oncology and clincial development.

AACR 2025: Brenus Pharma Presents Late-breaking Preclinical Data on its “off-the-shelf” Next-generation Vaccine-based Immunotherapy Candidate, STC-1010, Now Moving to Clinic

ASCO 2024: Brenus Pharma Presented “BreAK-CRC” First-in-human (FIH) Phase I/IIA Trial of STC-1010: a Next-generation Cancer Vaccine Targeting mCRC

AACR 2024: Brenus Pharma Unveils Promising and Robust Pre-clinical Efficacy Extrapolating Human Conditions with STC-1010